Maravai LifeSciences (MRVI) Tops Q4 EPS by 3c ; Offers Guidance

Maravai LifeSciences (NASDAQ: MRVI) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $49.02 million.

GUIDANCE:

Maravai LifeSciences sees FY2026 revenue of $200-210 million, versus the consensus of $203.3 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• Popular stocks with increasing option volume: MU SPCX INTC AMD SNDK IREN PLTR AVGO SOFI NKE MSTR NBIS ORCL